Clonal dominance of chronic myelogenous leukemia is associated with diminished sensitivity to the antiproliferative effects of neutrophil elastase.
Clinical observations suggest that in chronic myelogenous leukemia (CML), the Philadelphia chromosome (Ph+) clone has a growth advantage over normal hematopoiesis. Patients with CML have high levels of neutrophil elastase, which has recently been shown to antagonize the action of granulocyte-colony-stimulating factor (G-CSF) and other growth factors. We therefore compared the effect of elastase on the growth of normal and CML progenitor cells. In 10-day suspension cultures of normal or CML CD34+ cells supplemented with G-CSF, stem cell factor (SCF), and granulocyte macrophage-colony-stimulating factor (GM-CSF), CML cells had diminished sensitivity to the growth inhibitory effect of elastase. When equal numbers of CML and normal CD34+ cells were cocultured for 10 days, there was no change in the relative proportions of normal and leukemic cells (measured by fluorescence in situ hybridization [FISH] or flow cytometry). However, when elastase was added, CML cells predominated at the end of the culture period (78% vs 22% with 1 microg/mL and 80% vs 20% with 5 microg/mL elastase). CML neutrophils substituted effectively for elastase in suppressing the proliferation of normal CD34+ cells, but this effect was abrogated by serine protease inhibitors. These results suggest that elastase overproduction by the leukemic clone can change the growth environment by digesting growth factors, thereby giving advantage to Ph+ hematopoiesis.
El-Ouriaghli
Frank
F
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA.
Sloand
Elaine
E
Mainwaring
Lori
L
Fujiwara
Hiroshi
H
Keyvanfar
Keyvan
K
Melenhorst
J Joseph
JJ
Rezvani
Katayoun
K
Sconocchia
Giuseppe
G
Solomon
Scott
S
Hensel
Nancy
N
Barrett
A John
AJ
D002455:Cell Division; D002999:Clone Cells / Q000201:enzymology / Q000473:pathology; D018920:Coculture Techniques; D006133:Growth Substances / Q000494:pharmacology; D006412:Hematopoietic Stem Cells / Q000187:drug effects; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000201:enzymology* / Q000209:etiology / Q000473:pathology*; D019272:Leukocyte Elastase / Q000494:pharmacology* / Q000502:physiology; D014411:Neoplastic Stem Cells / Q000187:drug effects / Q000201:enzymology; D019899:Paracrine Communication; D014407:Tumor Cells, Cultured
D006133:Growth Substances; D019272:Leukocyte Elastase